Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reveal a consensus around the positive impact of sotatercept, with statements like 'incredibly promising' and mentions of lowered morbidity and mortality. The tone is optimistic and analytical, with many posts citing trial results, highlighting the drug’s potential to transform early-stage PAH treatment and emphasizing the importance of the findings for clinical practice.
Most discussions highlight the positive outcomes and support for the research, indicating general agreement with its significance.
People show high enthusiasm, mentioning terms like 'promising results' and 'incredible potential,' reflecting strong interest.
Several posts include specific references to trial data, the drug's mechanism, and implications for treatment, demonstrating active engagement.
The emphasis on reduced risks, fewer hospitalizations, and early-stage treatment implications suggests a recognition of significant real-world influence.
Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial) https://t.co/RbdA3ja1ji #ERSCongress | @EuroRespSoc https://t.co/CDy0Ps7xjp
3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor These are the first data that test the drug started within a year of diagnosis: the trial was stopped early for efficacy https://t.co/aKPf7ZfZc0 https://t.co/F5vwbULjhM
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, the addition of sotatercept to background therapy resulted in a lower risk of clinical https://t.co/GqS4JgHlln
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine https://t.co/oXFefn3ktw
診断後1年以内、WHO class Ⅱ,Ⅲの早期PAH(ただ2-3剤は既に入ってる)へのソタテルセプトのP3 HYPERION試験。 primary endpointは臨床的悪化の複合アウトカムのtime-to-first-event analysisだが、重篤例の試験すら余裕だったので当然のようにプラセボに差をつけ早期終了。 https://t.co/JotXdRrc9N
The most common causes of pulmonary arterial hypertension are unknown (idiopathic) and connective tissue disorders (like systemic sclerosis) It involves remodelling of the pulmonary vessels, which Sotatercept (an activin-signaling inhibitor) targets https://t.co/aKPf7ZfZc0 https://t.co/t0pFENziQU
This week, John Mandrola MD discusses translation science leading to beneficial drugs for heart diseases, with a focus on tafamidis treatment for transthyretin amyloid cardiomyopathy. Tafamidis stabilizes abnormal…
This week, John Mandrola MD explores significant findings on sotatercept, highlighting its ability to improve exercise capacity and reduce clinical worsening in patients with severe pulmonary arterial hypertension. This…
肺高血圧症は ソタテルセプトが有望 ・SOTERIA試験（長期安全性） https://t.co/vf3U3RGiq8 ・HYPERION試験（初期導入） https://t.co/7GUlgmfTOo
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine https://t.co/mUvymp0YmA
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @drbennisahmed: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arter…
RT @drbennisahmed: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arter…
RT @drbennisahmed: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arter…
RT @drbennisahmed: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arter…
RT @drbennisahmed: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arter…
RT @drbennisahmed: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arter…
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis Among adults with pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, the addition of sotatercept to background therapy resulted in a lower risk of clinical https://t.co/GqS4JgHlln
RT @tabibito250: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine ht…
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine https://t.co/MlaqSfEgzh
Sotatercept trial shows promise! In patients with PAH diagnosed within 1 year, significant reductions in morbidity & mortality observed. PMID:41025556, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2508170 #Medsky #Pharmsky #RNA #ASHG #ESHG
Sotatercept trial shows promise! In patients with PAH diagnosed within 1 year, significant reductions in morbidity & mortality observed. PMID:41025556, N Engl J Med 2025, @NEJM https://t.co/esiXB9Y2LG #AI #Pharma #BioMed #RNA #ASHG #ESHG
RT @DrSamuelBHume: 3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor Thes…
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine https://t.co/PB1gyGUSr2
RT @DrSamuelBHume: 3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor Thes…
RT @DrSamuelBHume: 3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor Thes…
RT @DrSamuelBHume: 3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor Thes…
RT @DrSamuelBHume: 3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor Thes…
RT @DrSamuelBHume: 3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor Thes…
3. Sotatercept in pulmonary arterial hypertension Sotatercept is a recently-approved activin-signalling inhibitor These are the first data that test the drug started within a year of diagnosis: the trial was stopped early for efficacy https://t.co/aKPf7ZfZc0 https://t.co/F5vwbULjhM
【RCT】診断1年未満、死亡リスクが高または中等度の2剤または3剤の基礎治療を受けているWHO機能分類IIまたはIIIの肺動脈高血圧患者へのソタテルセプトの投与は、プラセボの投与と比較して、臨床的悪化のリスク低下と関連した。（他試験の有益な結果から早期終了） #ペ読 https://t.co/O4a57yyaqO
Sotatercept for the treatment of PAH within the first year of diagnosis @NEJM @ATS_PC https://t.co/qLKNnBWadS
Among adults with pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, the addition of sotatercept to background therapy resulted in a lower risk of clinical worsening than placebo. Full HYPERION phase 3 trial results and Research Summary: nej.md/4mzuaY1
Sotatercept, un inhibidor de señalización de activina, ha demostrado reducir la morbilidad y mortalidad en pacientes con #hipertensiónarterialpulmonar. Sus efectos en pacientes diagnosticados durante el primer año no estaban claros previamente Leer aquí
The addition of sotatercept to background therapy resulted in a lower risk of clinical worsening than placebo. https://t.co/FCGJvUYt9U
RT @AlbertaPHdoc: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine h…
...to background therapy cut risk of clinical worsening by 76% vs placebo, with fewer hospitalizations, better exercise capacity, and no major side effects.
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
診断後1年以内、WHO class Ⅱ,Ⅲの早期PAH(ただ2-3剤は既に入ってる)へのソタテルセプトのP3 HYPERION試験。 primary endpointは臨床的悪化の複合アウトカムのtime-to-first-event analysisだが、重篤例の試験すら余裕だったので当然のようにプラセボに差をつけ早期終了。 https://t.co/JotXdRrc9N
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
El estudio nuevo https://t.co/NwXd3bTKcn
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
RT @NEJM: Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial)…
Original Article: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (HYPERION phase 3 trial) https://t.co/RbdA3ja1ji #ERSCongress | @EuroRespSoc https://t.co/CDy0Ps7xjp
Phase III positive pour le #sotatercept chez les patients récemment diagnostiqués avec une #HTAP https://t.co/FQyKtMUNUe https://t.co/qMnKM3s4hv
RT @AlbertaPHdoc: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine h…
RT @AlbertaPHdoc: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine h…
RT @AlbertaPHdoc: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine h…
The most common causes of pulmonary arterial hypertension are unknown (idiopathic) and connective tissue disorders (like systemic sclerosis) It involves remodelling of the pulmonary vessels, which Sotatercept (an activin-signaling inhibitor) targets https://t.co/aKPf7ZfZc0 https://t.co/t0pFENziQU
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine https://t.co/MlaqSfEgzh
“These results are incredibly promising for patients early in their journey with pulmonary arterial hypertension, which still has limited treatment options,” McLaughlin said. Check out the HYPERION study: https://t.co/KALcvmxOcE
RT @AlbertaPHdoc: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine h…
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | New England Journal of Medicine https://t.co/oXFefn3ktw